GlassScriptPhysician profile
Marsha S Smith
NPI 1528003548
$177,942.31
in general payments reported to CMS, 2019-2025
43 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,368 · 2020: $25K · 2021: $27K · 2022: $35K · 2023: $45K · 2024: $19K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Honoraria: $9,560 · Food and Beverage: $8,336 · Travel and Lodging: $6,988 · Consulting Fee: $5,440 · Education: $58.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,279.87 |
| Honoraria | $9,560.00 |
| Food and Beverage | $8,336.11 |
| Travel and Lodging | $6,988.08 |
| Consulting Fee | $5,440.00 |
| Education | $58.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $83,318.82 | 2020-2025 | Qulipta, Ubrelvy, Duopa |
| Kyowa Kirin, INC. | $43,246.60 | 2019-2024 | Nourianz |
| Allergan, INC. | $26,164.22 | 2019-2021 | |
| Mdd US Operations, LLC | $13,249.61 | 2022-2025 | Gocovri, Gocovri, Apokyn |
| Abbott Laboratories | $4,627.00 | 2019-2025 | Infinity |
| Boston Scientific Corporation | $1,817.36 | 2020-2025 | Vercise, General - Dbs |
| Medtronic, INC. | $1,140.06 | 2022-2025 | Percept PC Brainsense, Intellis Adaptivestim |
| Insightec,INC | $619.03 | 2023-2024 | Exablate |
| Sk Life Science, INC. | $528.22 | 2020-2025 | Xcopri |
| Biogen, INC. | $350.04 | 2019-2021 | |
| Genzyme Corporation | $313.32 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $244.78 | 2019-2025 | Dysport |
| Teva Pharmaceuticals USA, INC. | $216.15 | 2019-2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $210.18 | 2023-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $188.76 | 2019-2025 | Nuplazid |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marsha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.